Addressing Unmet Needs for Cholangiocarcinoma & Myeloid Lymphoid Neoplasms
Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
By
ASH 2022 Conference Coverage
FEATURING
Alessandro Vannucchi
By
ASH 2022 Conference Coverage
FEATURING
Alessandro Vannucchi
Login to view comments.
Click here to Login